Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

94
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
94
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

16
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

621
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
621

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Right Ventricular Metrics as End Points in Clinical Trials: A Review.

JAMA cardiology·2026
Same author

Comprehensive Clinical Benefit of CCM in HFrEF Patients - a win-ratio analysis of FIX-HF-5C randomized trial.

ESC heart failure·2026
Same author

Universal Pulmonary Resistance-Compliance Relationship: And Why It Matters?

Circulation. Heart failure·2026
Same author

De Novo Aortic Insufficiency and Its Progression in Patients on Microaxial Flow Pump Support Before Durable Left Ventricular Assist Device.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Cardiac microcurrent therapy in heart failure: Mechanistic rationale, early clinical evidence, and future directions.

Heart failure reviews·2026
Same author

Does Pacemaker Mode Affect Outcomes in Patients With HeartMate 3 LVAD?

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

REVEALing New Standards: Low Risk Redefined.

JACC. Heart failure·2026
Same journal

Implantable Cardioverter-Defibrillator Therapy in Contemporary Heart Failure Patients: An Analysis From the EMPEROR-Reduced Trial.

JACC. Heart failure·2026
Same journal

Sodium-Glucose Cotransporter 2 Inhibitor Following Left Ventricular Assist Device Implantation: A Randomized Controlled Trial.

JACC. Heart failure·2026
Same journal

Noninvasive Wearable-Based Algorithm to Predict Worsening Heart Failure by Change in Natriuretic Peptide Levels.

JACC. Heart failure·2026
Same journal

Long-Term HM3 Outcomes: Is Age the Signal or the Surrogate?

JACC. Heart failure·2026
Same journal

Impact of Age on Long-Term Clinical Outcomes Following HeartMate 3 LVAD Implantation: Insights From the MOMENTUM 3 Trial.

JACC. Heart failure·2026
See all related articles

Related Experiment Video

Updated: Jul 18, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K

Device Interventions for Heart Failure.

Husam M Salah1, Marat Fudim2, Daniel Burkhoff3

  • 1Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

JACC. Heart Failure
|August 23, 2023
PubMed
Summary
This summary is machine-generated.

Novel device-based interventions offer new hope for heart failure (HF) patients who remain symptomatic despite optimal drug therapy. These advanced therapies address unmet needs and limitations of current treatments for various HF phenotypes.

Keywords:
GDMTdevice interventionsdevice therapyheart failureinterventional heart failure

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K

Related Experiment Videos

Last Updated: Jul 18, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Medical Devices

Background:

  • Despite advances in drug therapy, heart failure (HF) continues to cause significant morbidity, mortality, and hospitalizations.
  • Many HF patients remain symptomatic even with optimal medical management, highlighting unmet clinical needs.

Purpose of the Study:

  • To review the evolving landscape of device-based interventions for heart failure (HF).
  • To highlight key considerations for implementing these novel therapies into current HF management workflows.

Main Methods:

  • Review of current literature on device-based interventions for HF.
  • Analysis of the advantages of device therapies over drug therapies.
  • Discussion of implementation challenges and workflow integration.

Main Results:

  • Novel device-based interventions are emerging as a promising therapeutic option for various HF phenotypes.
  • These devices can overcome limitations of drug therapy, including adherence issues and inconsistent delivery.
  • Device interventions may target HF pathophysiology more effectively than medications alone.

Conclusions:

  • Device-based interventions represent a significant advancement in treating heart failure.
  • Successful integration into clinical practice requires careful consideration of workflow and implementation strategies.
  • These therapies hold potential to improve outcomes for a broad range of HF patients.